Contact us at

Respiratory Health

Advancing respiratory health through innovative therapies

Hill-Rom® Respiratory Care

Respiratory Health at Home During COVID-19

Home Care Products and COVID-19

Helping you keep patients safe at home is our #1 priority, particularly during the COVID-19 pandemic.  High Frequency Chest Wall Oscillation (HFCWO) therapies have demonstrated the following to help patients stay out of the hospital.

  • Bronchiectasis patient outcomes:
    • 66% decrease in hospitalizations (p=0.0043).1
    • 46% decrease in IV antibiotic use (p=0.0106).1
    • 10% decrease in physician office visits (p=0.0013).1
  • Neuromuscular patient outcomes:
    • 20% reduction in in-patient admissions (p=0.004).2
    • 8% reduction in physician office visits (p=0.073).2

Are you considering if HFCWO may be helpful for one of your patients with a chronic respiratory condition? A screening tool may help.

Learn More

Hillrom can provide screening tools to support discussions with those who may have bronchiectasis, a neuromuscular condition, or ALS.  Contact Hillrom to learn more.

We are here to help your patients obtain an HFCWO device.  We continue to process prescriptions, ship, and train patients on their new device.  Here's how:

  • Hillrom provides options for HFCWO therapy with an air vest (The Vest® Airway Clearance System) or mobile vest for more active patients (Monarch® Airway Clearance System).  Both include an option to be connected-in-care for visibility to therapy data via the VisiView® Health Portal.
  • If you are newly considering HFCWO for bronchiectasis, Hillrom provides confidence knowing your patients will receive the therapy.  Our reimbursement specialists work diligently with insurance providers and achieve an 89% approval rate, with 31% of any denials overturned.3 Read more here.
    • Medicare coverage criteria for HFCWO for a patient diagnosed with bronchiectasis:4
      • Learn More

        Confirmed by a standard CT scan, which is characterized by:

        • Daily productive cough for at least six continuous months.


        • Frequent (i.e., three or more in a year) exacerbations requiring antibiotic therapy.

        AND there must be well-documented failure of standard treatments to adequately mobilize retained secretions.


  • We are committed to providing devices and clinical training as quickly as possible, even during these times.  Training options include in-home and virtual/remote.

Daily HFCWO therapy is now more important than ever, and Hillrom is here to help you with your patients' care.  If you have any questions about a particular patient or in general, contact Hillrom anytime at 800-426-4224.

    • After device training is complete, we follow up with patients to review their therapy and discuss any questions.
    • Do you have an upcoming telehealth visit with a patient who has a connected-in-care device,

The Vest®


Monarch® System


    • There are more than 9,000 patients with a Hillrom device connected-in-care.  You can review their therapy data in the VisiView® Health Portal and then discuss their day-to-day airway clearance progress during the call.  Read more here.

Hospital to Home

If you have a chronic respiratory patient in the hospital now who has received HFCWO therapy, consider prescribing them HFCWO to receive at home for daily use and to maintain lung hygiene.

  • You can place a hospital discharge order for The Vest® System:
    • Learn More

      Visit this page to read more.  Download the HFCWO device hospital discharge prescription form, fill out and fax to 800-870-8452.  Call Hillrom at 800-426-4224 if you have any questions.

  • We continue to prioritize hospital to home prescriptions to ensure that your patients can be discharged knowing that their airway clearance device and clinical training will be ready for them when they arrive home.
  1. Basavaraj A, DeKoven M, Shah D, et al. Impact of High Frequency Chest Wall Oscillation on Clinical Outcomes and Healthcare Resource Utilization in Adult Patients with Non-Cystic Fibrosis Bronchiectasis in the United States: A Pre-Post Cohort Analysis. ATS 2020.!/8998/presentation/9070.
  2. Lechtzin N, Wolfe LF and Frick KD. The Impact of High-Frequency Chest Wall Oscillation on Healthcare Use in Patients with Neuromuscular Diseases. Ann Am Thorac Soc 2016; 13 (6);904-9. DOI: 10.1513/AnnalsATS.201509-597OC.
  3. Hillrom internal data for HFCWO claim approvals for all payers, December 2017-November 2018.